Cargando…

Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials

BACKGROUND: Intravenous glucocorticoids are recommended for multiple sclerosis (MS). However, they can be inconvenient and expensive. Due to their convenience and low cost, oral glucocorticoids may be an alternative treatment. Recently, several studies have shown that there is no difference in effic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shuo, Liu, Xiaoqiang, Chen, Shuying, Xiao, Yingxiu, Zhuang, Weiduan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703548/ https://www.ncbi.nlm.nih.gov/pubmed/29176905 http://dx.doi.org/10.1371/journal.pone.0188644

Ejemplares similares

Neutrophil–lymphocyte ratio predicts the outcome of intracerebral hemorrhage: A meta-analysis
por: Liu, Shuo, et al.
Publicado: (2019)

Prognostic factors associated with survival in patients with anaplastic oligodendroglioma
por: Liu, Shuo, et al.
Publicado: (2019)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Selective serotonin reuptake inhibitors for functional independence and depression prevention in early stage of post-stroke: A meta-analysis
por: Zhou, Shaojiong, et al.
Publicado: (2020)

Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses
por: Caster, Ola, et al.
Publicado: (2015)

Prognostic Factors Associated With Survival in Patients With Diffuse Astrocytoma
por: Liu, Shuo, et al.
Publicado: (2021)

Hepatotoxicity after high‐dose intravenous methylprednisolone in multiple sclerosis patients
por: Hidalgo de la Cruz, Milagros, et al.
Publicado: (2017)

Association between red cell distribution width level and risk of stroke: A systematic review and meta-analysis of prospective studies
por: Li, Bingxian, et al.
Publicado: (2020)

Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
por: Then Bergh, Florian, et al.
Publicado: (2006)

Intravenous Methylprednisolone Versus Oral Prednisolone for West Syndrome: A Randomized Open-Label Trial
por: Kapoor, Dipti, et al.
Publicado: (2021)

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis
por: Brochet, Bruno, et al.
Publicado: (2017)

Venous Thrombosis in Multiple Sclerosis Patients after High-Dose Intravenous Methylprednisolone: The Preventive Effect of Enoxaparin
por: Kalanie, Hossein, et al.
Publicado: (2011)

Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse
por: Jongen, Peter Joseph, et al.
Publicado: (2016)

Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse
por: Möhn, Nora, et al.
Publicado: (2020)

Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis
por: Olyaeemanesh, Alireza, et al.
Publicado: (2016)

Methylprednisolone/tozinameran: Multiple sclerosis and lack of efficacy: case report
Publicado: (2022)

Intravenous Methylprednisolone Pulse Therapy Versus Intravenous Immunoglobulin in the Prevention of Coronary Artery Disease in Children with Kawasaki Disease: A Randomized Controlled Trial
por: Aslani, Nahid, et al.
Publicado: (2022)

Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with vasculitis of rheumatic disease
por: Rouster-Stevens, KA, et al.
Publicado: (2005)

Methylprednisolone versus intravenous immune globulin as an initial therapy in adult primary immune thrombocytopenia
por: Kim, Chul Hee, et al.
Publicado: (2019)

Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response
por: Evangelopoulos, Maria Eleftheria, et al.
Publicado: (2021)

Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients
por: Nociti, Viviana, et al.
Publicado: (2018)

Oral administration of methylprednisolone powder for intravenous injection dissolved in water to treat MS and NMOSD relapses during COVID-19 pandemic in a real-world setting
por: Luetic, Geraldine G., et al.
Publicado: (2021)

Safety of Intravenous Methylprednisolone in Refractory and Severe Pediatric Uveitis
por: Ghoraba, Hashem H, et al.
Publicado: (2022)

Intravenous pulse methylprednisolone for the treatment of severe COVID-19
por: Patoulias, Dimitrios, et al.
Publicado: (2023)

Protocol for a Cross-Sectional Study: Effects of a Multiple Sclerosis Relapse Therapy With Methylprednisolone on Offspring Neurocognitive Development and Behavior (MS-Children)
por: Kozik, Valeska, et al.
Publicado: (2022)

Myelin basic protein expression in thymoma after methylprednisolone administration for multiple sclerosis
por: Isono, Tomomi, et al.
Publicado: (2021)

Would it be recommended treating multiple sclerosis relapses with high dose oral instead intravenous steroids during the COVID-19 pandemic? Yes
por: Segamarchi, Constanza, et al.
Publicado: (2020)

Author Correction: Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response
por: Evangelopoulos, Maria Eleftheria, et al.
Publicado: (2021)

Erratum: Protocol for a cross-sectional study: effects of a multiple sclerosis relapse therapy with methylprednisolone on offspring neurocognitive development and behavior (MS-children)
Publicado: (2023)

The change of triglyceride-glucose index may predict incidence of stroke in the general population over 45 years old
por: Wu, Yaoling, et al.
Publicado: (2023)

Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis
por: Paul, Friedemann, et al.
Publicado: (2008)

Pathway-Based Analysis of the Liver Response to Intravenous Methylprednisolone Administration in Rats: Acute Versus Chronic Dosing
por: Acevedo, Alison, et al.
Publicado: (2019)

High-dose intravenous methylprednisolone for the prophylactic treatment of cluster headache
por: Kawada, Sanami, et al.
Publicado: (2013)

Pulse Methylprednisolone with Oral Prednisolone versus Adrenocorticotropic Hormone in Children with West Syndrome: a Randomized Controlled Trial
por: Fatema, Kanij, et al.
Publicado: (2021)

Acute Urticaria Induced by Oral Methylprednisolone
por: Jang, Eun Jung, et al.
Publicado: (2011)

Factors associated with relapses in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis
por: Xie, Yao, et al.
Publicado: (2020)

Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial
por: Massacesi, Luca, et al.
Publicado: (2014)

Relapse After Methylprednisolone Oral Minipulse Therapy in Childhood Vitiligo: A 12-Month Follow-Up Study
por: Majid, Imran, et al.
Publicado: (2013)

Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
por: Guarnera, Cristina, et al.
Publicado: (2017)

Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a0u71u4cemlu2khpc0s2os9v4j